back to Meetings page
- IMMPACT-XII Slide Presentations
- 1. Meeting objectives and deliverables
- Sandra Comer, PhD and James Zacny, PhD
- 2. General considerations in developing and evaluating outcome measures of abuse liability
- Laurie Burke, RPh, MPH
- 3. A historical perspective on human abuse liability studies
- Donald Jasinski, MD
- 4. Physiologic outcome measures
- Edward Sellers, MD, PhD
- 5. Performance outcomes measures
- James Zacny, PhD
- 6. Subjective outcome measures
- George Bigelow, PhD
- 7. Behavioral outcome measures
- Sandra Comer, PhD
- 8. Data analysis
- Richard Foltin, PhD
- 9. A regulatory perspective on what is needed for evaluating abuse liability in analgesic clinical trials
- Bob Rappaport, MD
- 10. Toward a classification of abuse-related outcomes
- Nat Katz, MD
- 11. Clinical assessment of abuse-related outcomes
- Charles O'Brien, MD, PhD
- 12. Patient-reported and interviewer-rated abuse-related outcomes (e.g., COMM, ABC)
- Jennifer Haythornthwaite, PhD
- 13. Urine drug screening in analgesic clinical trials
- Gary Reisfield, MD
- 14. Study drug monitoring and diversion in analgesic clinical trials
- Robert Colucci, PharmD
- 15. The development of the Columbia Classification Algorithm of Suicide Assessment (C-CASA)
- Kelly Posner, PhD
- 16. Retrospective and prospective classification of abuse-related adverse events in analgesic clinical trials
- Nat Katz, MD
- 17. Discussant: FDA abuse liability review
- Michael Klein, MD